Ursodeoxycholic Acid: all 96 studies that test it

Page 1 of 1. Open to participants first (17), then studies with results posted, then the rest; newest registration first within each.

• Effect of Adjunctive Ursodeoxycholic Acid on Oxidative Stress, Inflammation, and Organ Dysfunction in Adults With SepsisNot yet recruitingNCT07852780Phase 2/3
• Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder CancerRecruitingNCT07717242Phase 2
• Perioperative Ursodeoxycholic Acid for Renal Protection in Adults Undergoing Partial Nephrectomy for Renal TumorsRecruitingNCT07672860Phase 2
• Effect of Ursodeoxycholic Acid Supplementation on Liver Regeneration in Adult Living Donor Liver Transplant (LDLT) Recipients.Not yet recruitingNCT07664020Not applicable
• Comparative Evaluation of Oral Ursodeoxycholic Acid in Reducing Bilirubin Levels Among Patients With Acute Viral HepatitisNot yet recruitingNCT07525401Not applicable
• Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic HepatitisRecruitingNCT07378761Phase 2
• UDCA to Prevent Post-TIPS Hepatic EncephalopathyNot yet recruitingNCT07273734Not applicable
• The Efficacy of Ursodeoxycholic Acid (UDCA) as Adjuvant Therapy to Phototherapy in the Management of Neonatal Indirect HyperbilirubinemiaRecruitingNCT07110987Not applicable
• Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard TherapyNot yet recruitingNCT06884748Early Phase 1
• PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast CancerNot yet recruitingNCT06842472Phase 2
• Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose ToleranceRecruitingNCT06684106Not applicable
• Efficacy and Safety of Ursodeoxycholic Acid in Reversing Gastric Intestinal MetaplasiaRecruitingNCT06610760Phase 4
• Ursodeoxycholic Acid (UDCA) as a Neuroprotective Adjuvant Treatment to Rhegmatogenous Retinal Detachment SurgeryRecruitingNCT06294847Phase 3
• Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes MellitusRecruitingNCT05902468Phase 2/3
• A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-InfectionNot yet recruitingNCT05467553Phase 2
• Ursodeoxycolic Acid for the Prevention of Relapsing Complications After Gallstone Acute PancreatitisRecruitingNCT04924868Phase 3
• Clinical Research of Tapering UDCA in PBC Patients With a Complete ResponseRecruitingNCT04650243Phase 4
• Ursodeoxycholic Acid (UDCA) for Hepatic SarcoidosisTerminatedNCT03602976Phase 2Results posted
• C. Difficile and UrsodiolCompletedNCT02748616Phase 4Results posted
• Ursodiol on Insulin Sensitivity, Gastric Emptying and Body Weight With Type 2 Diabetes on MetforminCompletedNCT02033876Phase 2Results posted
• Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade DysplasiaCompletedNCT01097304Phase 2Results posted
• Ursodiol 500 mg Tablets Under Fed ConditionsCompletedNCT00909753Phase 1Results posted
• Ursodiol Tablets 500 mg Under Fasting ConditionsCompletedNCT00909610Phase 1Results posted
• Clinical Studies on Bile Acids in Barrett's EsophagusCompletedNCT00858858Not applicableResults posted
• Thyroid Hormones Homeostasis and Energy Metabolism Changes During Stimulation of Endogenously Secreted Bile Acids (BAs)CompletedNCT00706381Phase 3Results posted
• Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)TerminatedNCT00550862Phase 2Results posted
• Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis CCompletedNCT00200343Phase 3Results posted
• Trial of High-dose Urso in Primary Sclerosing CholangitisTerminatedNCT00059202Phase 2/3Results posted
• Effect of Ursodeoxycholic Acid on Indirect Hyperbilirubinemia in Neonates Treated With PhototherapyCompletedNCT07867366Not applicable
• Remedial Mechanism of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk of Bile Secretion, Gut Microbiome, and Host Immune ResponseTerminatedNCT07102979Not applicable
• Hepatoprotective Measures for Children at High Risk of NAFLDActive, not recruitingNCT06918080Phase 4
• Efficacy & Safety of Oral Adjuvants to Phototherapy in Neonatal HyperbilirubinemiaCompletedNCT06517862Phase 4
• Gestational Treatment With Ursodeoxycholic Acid Compared to Placebo to Reduce Severity of Gestational Diabetes Mellitus Diagnosed at 24-28 Weeks' GestationCompletedNCT06127355Phase 3
• Effect of Ursodeoxycholic Acid Supplementation on Liver Regeneration on Right Lobe Donor HepatectomyCompletedNCT06091787Not applicable
• Evaluating the Effect of Ursodeoxycholic Acid in Patients With Rheumatoid ArthritisCompletedNCT05973370Phase 2
• An Exploratory Clinical Trial to Evaluate and Compare Safety and Pharmacokinetic Characteristics After Administration of the DWJ1439, DWJ1464, DWC202108 or DWC202109 in Healthy Adult VolunteersCompletedNCT05832697Phase 1
• Prophylactic Effect of Nirmatrelvir/Ritonavir and Ursodeoxycholic Acid on Reducing Complications After Cardiac SurgeryCompletedNCT05690646Phase 4
• The Application of Ursodeoxycholic Acid for the Prevention of SARS-CoV-2 Infection (COVID-19)CompletedNCT05659654Phase 1/2
• Ursodeoxycholic Acid in C. Difficile InfectionTerminatedNCT05526807Not applicable
• Effect of UDCA on the New Onset Diabetes and Glucose Intolerance Induced by StatinStatus unknownNCT05500937Phase 2/3
• Efficacy of Ursodeoxycholic Acid (UDCA) in Patients With Type 2 DiabetesStatus unknownNCT05416580Phase 3
• Ursodeoxycholic Acid Prevents Total Parenteral Nutrition CholestasisStatus unknownNCT05043194Not applicable
• Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Non-alcoholic Steatohepatitis (NASH) PatientsCompletedNCT04977661Phase 4
• Ursodeoxycholic Acid (Udca) as a Local Drug Delivery Agent in the Treatment of Intra-bony DefectsStatus unknownNCT04937023Not applicable
• Follow-up of NAFLD Patients With MRI-PDFFCompletedNCT04910178Phase 4
• Evaluating the Effect of Digoxin and Ursodeoxycholic Acid in Patients With Rheumatoid ArthritisCompletedNCT04834557Phase 2
• Pancreatic Enzymes and Bile Acids in Acutely Ill Severely Malnourished ChildrenStatus unknownNCT04542473Phase 2/3
• Ursodeoxycholic Acid vs Metformin in Gestational Diabetes MellitusActive, not recruitingNCT04407650Phase 4
• Trial of Ursodeoxycholic Acid (UDCA) for Parkinson's Disease: The "UP" StudyCompletedNCT03840005Phase 2
• The Role of Secondary Bile Acids in Intestinal InflammationTerminatedNCT03724175Phase 2/3
• Impact of Ursodeoxycholic Acid, Silymarin, Antioxidants and Colchicine on Fibrosis Regression in HCV After SVRCompletedNCT03659058Not applicable
• A Single-dose, Comparative Bioavailability Study of Two Formulations of Ursodiol 500mg Tablets Under Fed ConditionsCompletedNCT03512821Phase 1
• A Single-dose, Comparative Bioavailability Study of Two Formulations of Ursodiol 500mg Tablets Under Fasting ConditionsCompletedNCT03512808Phase 1
• Development of Ursodeoxycholic Acid 300 mg at Hospital Das Clinicas of the University of São Paulo School of MedicineCompletedNCT03489889Not applicable
• Examination of the Metabolic Effects of Direct Bile Salt Delivery to the Ileum in HumansTerminatedNCT03201952Phase 1
• Metformin in Intrahepatic Cholestasis of PregnancyStatus unknownNCT03056274Phase 2/3
• Therapeutic Effect of Ursodeoxycholic Acid in Functional DyspepsiaActive, not recruitingNCT03004118Phase 4
• Evaluation of PK and Biomarkers After UDCA Administrations to Subjects Who Are Overweight and Have Liver ProblemsStatus unknownNCT03000218Phase 1
• Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA TreatmentCompletedNCT02967250Phase 1
• Ursodeoxycholic Acid for Rhegmatogenous Retinal DetachmentCompletedNCT02841306Phase 1
• Clinical Trial to Investigate Pharmacokinetics, Metabolomics and Biomarker in Elderly After UDCA AdministrationStatus unknownNCT02789644Phase 1
• Effectiveness of Ursodeoxycholic Acid Use in the Prevention of Gallstone Formation After Sleeve GastrectomyStatus unknownNCT02721862Phase 3
• A Multiple Dose Study of DWP10292 and UDCA in Healthy Male SubjectsCompletedNCT02622685Phase 1
• The Role of Ursodeoxycholic Acid in Treatment of Gallstones in Hemolytic DisordersTerminatedNCT02472509Phase 4
• A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of 'Ursa Complex Soft Cap. (UDCA-004)' in Patients With Physical Fatigue.CompletedNCT02418130Phase 4
• Clinical Trial to Evaluate the Efficacy and Safety of 'URSA SOFT CAP. (UDCA-003)' in Fatigue Patients With Liver DysfunctionCompletedNCT02415777Phase 4
• Comparative Bioavailability Study of UDCACompletedNCT02385032Phase 1
• Effects of Bile Acids on GLP-1 Secretion After Roux-en-Y Gastric BypassCompletedNCT02340247Phase 4
• Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal DialysisStatus unknownNCT02338635Phase 4
• Preventive Therapy With Ursodiol to Reduce the Incidence of Gallstones Formation in Patients After Bariatric SurgeryStatus unknownNCT02319629Not applicable
• Ursodeoxycholic Acid as Treatment for Polycystic Liver DiseaseCompletedNCT02021110Phase 2
• The Preventative and Therapeutical Effect of Ursodeoxycholic Acid(UDCA) to Short Bowel Syndrome PatientsCompletedNCT01974336Phase 4
• The Effect of Ursodeoxycholic Acid in Liver Functional Restoration of Patients With Obstructive JaundiceStatus unknownNCT01688375Phase 2
• Ursodeoxycholic Acid in the Treatment of Intrahepatic Cholestasis of PregnancyCompletedNCT01576458Phase 3
• Ursodeoxycholic Acid in Bariatric SurgeryCompletedNCT01548079Not applicable
• Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary CirrhosisCompletedNCT01510860Phase 4
• Auto Transplant for High Risk or Relapsed Solid or CNS TumorsCompletedNCT01505569Not applicable
• Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver DiseasesStatus unknownNCT01337440Phase 4
• Ursodeoxycholic Acid And Cholestasis Of PregnancyWithdrawnNCT01226823Phase 3
• Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver ToxicityCompletedNCT01149304Phase 2
• Cholestatic Drug-induced Liver InjuryStatus unknownNCT01141322Phase 4
• Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing CholangitisCompletedNCT01088607Phase 1
• Effects of Ursodeoxycholic Acid on Graft Recovery Early After Adult Liver TransplantationCompletedNCT01073202Not applicable
• Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal CancerCompletedNCT00873275Phase 1
• Ursodiol for Treating Parenteral Nutrition Associated Cholestasis in NeonatesCompletedNCT00846963Phase 2/3
• Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous PolyposisCompletedNCT00808743Phase 2/3
• Pharmacokinetic Investigation of UDCA in Bile and SerumCompletedNCT00529009Phase 1
• Ursodiol in Huntington's DiseaseStatus unknownNCT00514774Phase 1
• Pilot Study of Ursodesoxycholic Acid in Non-Alcoholic SteatohepatitisCompletedNCT00470171Phase 2
• Ursodeoxycholic Acid in Chronic Heart FailureStatus unknownNCT00285597Phase 2
• UDCA for Symptomatic Gallstone DiseaseCompletedNCT00161083Phase 4
• Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) PatientsStatus unknownNCT00134758Phase 2/3
• Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal CancerTerminatedNCT00062023Phase 2
• Lithotripsy for the Treatment of GallstonesTerminatedNCT00042549Phase 4
• Phase III Randomized Study of Ursodiol With Vs Without Methotrexate for Primary Biliary CirrhosisCompletedNCT00004784Phase 3
• Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver DiseaseStatus unknownNCT00004315Phase 2

← Ursodeoxycholic Acid overview